![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Bio-Techne’s Prostate Cancer Test Grabs Breakthrough Device Designation
Bio-Techne’s Prostate Cancer Test Grabs Breakthrough Device Designation
![](https://www.fdanews.com/ext/resources/test/Device_Images6/BioTechne_Logo.gif?t=1576260674&width=430)
The FDA has handed Bio-Techne breakthrough device designation for its ExoDx Prostate Intelliscore test, a diagnostic used to assess a man’s risk of prostate cancer.
The non-invasive test uses a urine sample to perform a liquid biopsy for prostate cancer and is uniquely able to identify high-grade prostate cancer at the time of biopsy and surgery.
“This assay [has the] ability to give urologists a more precise, genetically informed understanding of a man’s risk for aggressive disease via a simple urine sample, without the need for an invasive prostate tissue biopsy,” said Charles Kummeth, president and CEO of Bio-Techne.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct